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ABSTRACT
Reg4 is highly expressed in gastrointestinal malignancies and acts as a 
mitogenic and pro-invasive factor. Our recent works suggest that Reg4 binds with 
CD44 and induces its proteolytic cleavage to release intra-cytoplasmic domain of 
CD44 (CD44ICD). The goal of this study is to demonstrate clinical significance of the 
Reg4-CD44/CD44ICD pathway in stage II/III colon cancer and its association with 
clinical parameters of aggression. We constructed a tissue microarray (TMA) of 93 
stage II/III matched colon adenocarcinoma patients, 23 with recurrent disease. The 
TMA was immunohistochemically stained for Reg4, CD44, and CD44ICD proteins and 
analyzed to identify associations with tumor characteristics, recurrence and overall 
survival. The TMA data analysis showed a significant correlation between Reg4 and 
CD44 (r2 = 0.23, P = 0.028), CD44 and CD44ICD (r2 = 0.36, p = 0.0004), and Reg4 
and CD44ICD (r2 = 0.45, p ≤ 0.0001). Reg4 expression was associated with larger 
tumor size (r2 = 0.23, p = 0.026). Although, no association was observed between 
Reg4, CD44, or CD44ICD expression and disease recurrence, Reg4-positive patients 
had a median survival of 4 years vs. 7 years for Reg4-negative patients (p = 0.04) 
in patients who recurred. Inhibition of the Reg4-CD44/CD44ICD pathway may be a 
future therapeutic target for colon cancer patients.
INTRODUCTION
Colorectal cancer (CRC) is the third most common 
cancer diagnosed in both men and women in the United 
States. The American Cancer Society estimates 101,420 
new cases of colon cancer, 44,180 new cases of rectal 
cancer and about 51,020 deaths from CRC in the United 
States for 2019. While stage I CRC is overwhelmingly 
curable with resection, metastatic or stage IV disease is 
commonly fatal with a 5-year survival rate of 15% and 
requires a multidisciplinary approach with a chemotherapy 
backbone [1]. For locally advanced (stage II) and node 
positive (III) disease the approach is still curative, but 
5-year survival rates range from 50–80%, with mortality 
ascribed to recurrent disease [2–4]. After surgical 
resection, stage II patients are either observed or offered 
chemotherapy if deemed clinically high-risk, while 
stage III patients receive anywhere from 3 to 6 months 
of adjuvant 5-FU based treatment [5]. Chemotherapy in 
stage II and III disease is hypothesized to treat micro-
metastases that account for disease recurrence following 
surgery [6–8].
Reg4 protein, encoded by a member of the 
regenerating (Reg) multigene family is a secretory islet-
derived protein involved in growth and differentiation 
of cells, originally discovered through a high throughput 
assay of an ulcerative colitis library [9]. Reg4 has been 
demonstrated to precipitate an aggressive neoplastic 
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phenotype marked by increased mortality in CRC 
patients [10, 11]. Reg4 is associated with anti-apoptotic 
mechanisms as demonstrated by in vitro resistance to 
5-FU chemotherapy and radiation [12–14]. While the 
mechanism of Reg4 has long remained a mystery, our 
research group has recently observed that exogenous 
Reg4 acts through the extracellular CD44 receptor and can 
trigger intramembranous proteolysis of CD44 to release its 
intracytoplasmic domain (CD44ICD) into the cytoplasm. 
CD44 then undergoes translocation to the nucleus 
activating transcription of a series of pro-proliferative, 
pro-metastatic and anti-apoptotic genes such as KLF4 and 
SOX-2 (data unpublished). Various studies corroborate 
that CD44ICD triggers a series of “stemness factors” in 
the nucleus such as Nanog, Sox-2, and Oct-4 that lead 
to a pro-metastatic cancer phenotype with increased 
tumorigenicity [15, 16]. Given the interplay between 
Reg4 and colorectal cancer aggressiveness, we sought 
to investigate if expression of Reg4 and its downstream 
proteins are associated with clinical recurrence and overall 
survival in stage II and III colorectal cancer patients 
treated with curative intent. 
RESULTS
Patient characteristics
Patient characteristics were as follows: Rectal 
cancer patients were excluded. Age ranged between 50 
to 80, without history of neo-adjuvant chemotherapy or 
radiation prior to resection. Forty-four of these patients 
were TNM stage 2A, four were 3A, forty were 3B, and 
five were stage 3C. Of stage II patients, 32% of patients 
received chemotherapy (14/44) while 100% of stage III 
CRC patients (49/49) received chemotherapy, consistent 
with current guidelines. Out of 93 patients, 24 patients had 
recurrent disease and the other 69 survived at least 5 years 
after surgical resection without recurrence. 
TMA evidence of Reg4-CD44-CD44ICD 
pathway
Prior to our principal analysis, we confirmed the 
homogeneity of protein expression between the two cores. 
A chi-squared analysis revealed no significant association 
of percent protein expression or staining intensity between 
duplicate tumor cores for either Reg4, CD44, or CD44ICD 
for each patient.
We then examined the correlation between 
Reg4, CD44, and CD44ICD for each patient to explore 
whether this in vitro studied mechanism was clinically 
valid. We utilized a Spearman’s correlation to study the 
association between each of these proteins using percent 
mean expression (0–100%), mean intensity (0, 1, 2, 3), 
and H-score as determined blindly by the pathologist. As 
shown in Figure 1, a significant Spearman correlation of 
mean percent expression was observed between Reg4 
and CD44 (ρ = 0.23, P = 0.025), CD44 and CD44ICD 
(ρ = 0.31, p = 0.0026), and Reg4 and CD44ICD (ρ = 
0.42, p ≤ .0001). Mean protein intensity also revealed a 
significant association between Reg4 and CD44 (ρ = 0.23, 
P = 0.028), CD44 and CD44ICD (ρ = 0.36, p = 0.0004), 
and Reg4 and CD44ICD (ρ = 0.45, p ≤ .0001). The 
strongest association in the pathway was observed 
between Reg4 and CD44ICD.
A representative immunostaining expression of 
Reg4, CD44 and CD44ICD proteins in our TMA core 
from representative positive and negative samples is 
shown in Figure 2. In CRC patients, increased expression 
of CD44 was localized in the membranous part of the 
colonic cells, whereas Reg4 and CD44ICD were expressed 
at higher levels in either cytoplasmic and/or nuclear parts 
of the cells. This correlated expression of Reg4, CD44 
and CD44ICD establishes an important axis of Reg4-
CD44-CD44ICD, a hallmark suggesting a crucial role in 
colorectal cancer biology.
Protein expression and tumor characteristics
We then looked at accepted prognostic factors 
and protein expression. Laterality (left vs right) and 
MMR status had no correlation with expression of the 
three proteins. MMR deficient patients had an average 
Reg4 mean expression of 20.5% compared to 34.6% 
expression in MMR intact patients (p = 0.10). However, 
tumor differentiation did show an association. CD44 
mean percent expression (r2 = 0.26, p = 0.013) and mean 
intensity (r2 = 0.26, p = 0.012) both correlated with 
higher grade tumors. Reg4 mean expression (r2 = 0.23, p 
= 0.026) and mean intensity (r2 = 0.21, p = 0.039) were 
both associated with larger tumor size. Tumors cores with 
> 50% Reg4 staining were associated with larger tumors 
than tumors with < 50% Reg4 staining; 4.46 cm (3.99–
4.93) vs. 6.07 cm (4.67–7.47); p = 0.043. 
Protein expression and mortality in recurrent 
disease
Kaplan-Meier survival curves were constructed for 
patients that had recurrent disease after initial resection (n = 
24). Protein expression from tumor core at initial resection 
was correlated with time, in years, from initial surgical 
resection to death. No association was found with either 
CD44 or CD44ICD expression and mortality once patients 
developed recurrent disease. Conditional logistic analysis 
revealed no significant association between disease 
recurrence and mean percent Reg4 (p = 0.95), CD44 (p = 
0.36), or CD44ICD (p = 0.58) expression. Furthermore, no 
significant association with recurrence was detected with 
mean intensity of Reg4 (p = 0.72), CD44 (p = 0.30), and 
CD44ICD (p = 0.63) or H-score. However, Reg4 positivity 
was associated with significantly higher mortality in 
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stage II and III patients who developed recurrent disease. 
In patients who recurred, Reg4-positive cases at initial 
resection had a median survival time of 4 years [95% CI: 
4–10] versus 7 years [95% CI: 2–5] for Reg4-negative 
cases (p = 0.04). Figure 3 displays the Kaplan-Meier curves 
relating protein expression with time to death in years after 
initial surgical resection. 
Peptides inferring CD44ICD activity inhibit 
CRC cell proliferation and stemness
We performed in vitro experiments using HT29 
and SW480 colorectal cancer cell lines using these 
peptides to interfere with endogenous CD44ICD and 
to block Reg4-mediated effects. Following WST1 cell 
proliferation assay as shown in Figure 4, we observed 
a Reg4-mediated increase in cell proliferation (ap < 
0.05). Addition of CD44ICD interfering peptides to 
the cultures of these cells either reduced the rate of cell 
proliferation and/or blocked the pro-proliferative effect 
of Reg4. We used either lower concentration of double 
phosphorylated Pen-CD44ICD (DP: 1 μg/ml) or higher 
concentration of non-phosphorylated Pen-CD44ICD (NP: 
50 μg/ml) as experimental controls showing either no 
effect on the rate of cell proliferation or no blocking of 
Reg4-mediated increase in cell proliferation. However, 
single phosphorylated Pen-CD44ICD (SP: 50 μg/ml) 
significantly blocked Reg4-mediated increase in cell 
proliferation, while double phosphorylated Pen-CD44ICD 
(DP: 50 mg/ml) significantly reduced the rate of cell 
proliferation as well as blocked Reg4-mediated effects.
We further determined the effect of CD44ICD-
interfering peptides in Reg4-mediated survival of CRC 
stem cells. As assessed by spheroid formation assays 
using HCT116 and HT29 CRC cells shown in Figure 5, 
treatments of with a single dose of single phosphorylated 
Pen-CD44ICD (SP: 50 μg/ml), and double phosphorylated 
Pen-CD44ICD (DP: 50 μg/ml) led to a significant 
Figure 1: Spearman’s correlation between Reg4, CD44, and CD44ICD protein expression in human CRC patients. 
Percent mean expression (0–100%) and mean intensity of individual protein expression (0, 1, 2, and 3) was scored blindly by the pathologist. 
Data analysis shows: a significant correlation of percent mean expression and mean protein intensity between Reg4 and CD44, CD44 and 
CD44ICD, and Reg4 and CD44ICD. The correlation between Reg4 and CD44ICD was strongest among them.
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reduction in the number and size of spheroids, whereas 
no change was noted with similar treatments of non-
phosphorylated Pen-CD44ICD (NP) (panel A: upper). A 
graphical representation of data is shown in lower panel A, 
where lower dose of NP, SP and DP (1 μg/ml and 10 μg/
ml) showing no significant changes in the number and size 
of spheroids served as additional experimental controls. 
As an extension of this experiment, we used double 
phosphorylated Pen-CD44ICD (DP: 50 μg/ml) with and 
without Reg4 and performed similar spheroid formation 
assays using HCT116 and HT29 CRC cells. Assessing the 
number and size of spheroids in culture, Pen-CD44ICD 
(DP) treatment blocked Reg4-mediated effect (panel B). 
Results of this study demonstrated an involvement 
of Reg4-mediated generation of nuclear CD44ICD 
regulating proliferation and stemness of human CRC cells. 
These results also identify CD44ICD as a potential target 
of therapeutic interventions for human CRC patients. 
DISCUSSION 
In this study, we constructed a TMA of 94 stage 
II and III colon cancer patients matched by patient/
tumor characteristics and disease recurrence. We 
immunohistochemically stained our TMA with three 
proteins integral to the Reg4 pathway: Reg4, CD44, and 
CD44ICD and looked into associations with clinical 
parameters of tumor aggression. We found that Reg4 
expression is associated with larger tumors and higher 
mortality in metastatic disease, but not with recurrence 
risk per se. We also confirmed that the Reg4-CD44-
CD44ICD is a relevant pathway in the clinical setting. 
Reg4 is a secretory islet-derived protein involved 
in growth and differentiation originally discovered 
through a high throughput assay of an ulcerative colitis 
library [9, 17]. Reg4 exerts its effects in a paracrine and 
autocrine fashion precipitating an aggressive neoplastic 
Figure 2: A representative immunostaining expression of Reg4, CD44 and CD44ICD proteins in CRC TMA core 
showing representative positive and negative samples. Microphotographs shows increased staining of CD44 in membranous part 
of the colonic cells, whereas increased staining of Reg4 and CD44ICD are localized either in cytoplasmic or/and nuclear parts of the cells. 
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phenotype marked by increased mortality in CRC patients, 
as confirmed in our study [18, 19]. In vitro studies have 
shown that Reg4 promotes migration and invasion of 
CRC tumor cells with reversal of this phenomenon 
upon treatment with anti-Reg4 antibody [18, 20]. Mouse 
models have demonstrated Reg4 to promote gastric cancer 
adhesion to murine peritoneum in vivo [21] and a patient 
cohort associated Reg4 levels of peritoneal washings 
with peritoneal micro-metastasis [22]. In our lab, we 
successfully used a CD44ICD interrupting peptide to 
inhibit Reg4 induced proliferation. Reg4 acts as a growth 
factor with exogenous Reg4 stimulating growth and in 
vitro invasiveness of colon cancer cells [23–25]. 
The role of Reg4 and treatment resistance is still 
being elucidated. Our lab has previously demonstrated that 
exogenous Reg4 added to human colon adenocarcinoma 
cells leads to upregulation of the anti-apoptotic gene bcl-
2 and induces resistance in vitro to ionizing irradiation 
Figure 3: Kaplan-Meier survival curves for patients that had recurrent disease after initial resection (n = 24). Protein 
expression of Reg4, CD44 and CD44ICD from tumor core at initial resection was correlated with time, in years, from initial surgical 
resection to death. Conditional logistic analysis revealed association of Reg4 with significantly higher mortality in stage II and III patients 
who developed recurrent disease. 
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[13] and 5-FU chemotherapy [12]. In 2002, a study 
by Violette et al. demonstrated that the Reg4 gene is 
upregulated in drug-resistant HT-29 colon cancer cell 
lines and downregulated in drug sensitive cell lines 
[12]. In gastric cancer lines, SiRNA knockdown of Reg4 
promoted 5-FU induced apoptosis with no change in 5-FU 
metabolites inferring a novel resistance pathway [26]. 
Recently, knockout of Reg4 in mice suppressed colon 
cancer stem cell markers and in a patient cohort, Reg4 
was significantly associated with CRC stem cell markers 
[27]. These studies suggest that high levels of Reg4 in 
colon adenocarcinoma confer a survival advantage when 
exposed to 5-FU. Our study also showed that in stage II 
and III patients who developed recurrent disease, Reg4 
expression was associated with significantly higher 
mortality. 
Although we didn’t observe an association 
between Reg4 expression and recurrence risk in this 
study, possibly due to limited number of samples, our 
results clearly demonstrated that the expression of 
Reg4 promotes tumor growth and chemoresistance. In 
2015, Zhu et al. demonstrated that Reg4 expression in 
combination with MMP-7 in clinical CRC resections 
was significantly associated with lymph node disease, T 
stage, clinical stage, metastasis and decreased survival 
[10]. However, this study looked into a much broader 
population, including very few (< 10%) metastatic 
patients and did not perform a subgroup analysis to 
determine what drove the increased mortality [10]. A 
cohort of 202 CRC patients demonstrated that Reg4 
mRNA expression in tumors was an independent 
predictor of survival at 5 years [11]. Interestingly, 
in prostate cancer, Reg4 has been shown to be an 
independent predictor of relapse after prostatectomy [28] 
and in gastric cancer associated significantly with tumor 
invasion depth, lymph node metastasis, and increased 
mortality [29]. In gastric cancer, in vitro Reg4 antibody 
has inhibited gastric cancer proliferation and enhanced 
the apoptotic effect of 5-FU [30]. 
We propose that Reg4 promotes local invasion, 
proliferation, and properties of chemo-resistance; but 
is not directly implicated in the development of distant 
metastasis. This can explain why Reg4 positive patients 
tend to have less differentiated and larger tumors yet are 
not more likely to recur after resection in early-stage 
disease. In the metastatic setting, tumors that express 
Figure 4: Pen-CD44ICD peptides interfering endogenous nuclear CD44ICD activity inhibit CRC cell proliferation. 
As assessed by WST-1 cell proliferation assay using HT29 and SW480 CRC cells, treatment of Reg4 increased rate of cell proliferation, 
whereas Pen-CD44ICD peptides either reduced the rate of cell proliferation and/or blocked the pro-proliferative effect of Reg4. A lower 
concentration of DP (1 μg/ml) and higher concentration of NP (50 μg/ml) were used as experimental controls showing either no effect on 
the rate of cell proliferation or no blocking of Reg4-mediated increase in cell proliferation. However, SP (50 μg/ml) significantly blocked 
Reg4-mediated increase in cell proliferation, and DP (50 μg/ml) significantly reduced the rate of cell proliferation as well as blocked Reg4-
mediated increase in cell proliferation. (ap < 0.05 vs Con; *p < 0.05; **p < 0.01). 
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high levels of Reg4 are less responsive to 5-FU regimens, 
leading to increased mortality. The idea of stage specific 
prognostic biomarkers in cancer is not new [31]. For 
example, Kirsten rat sarcoma virus (KRAS) mutations 
are associated with worse disease-free survival [HR 1.29 
p = .008] amongst stage III CRC patients, but no survival 
difference in stage II disease. KRAS mutations are used to 
choose treatments in the metastatic and inoperable setting 
[32–34]. Microsatellite instability is associated with a 
better prognosis in stage II and III colon cancer; but has 
no prognostic implications in metastatic disease treated 
with standard therapy [35]; although this is currently 
changing with the use of immunotherapy [36, 37]. In other 
malignancies such as melanoma, BRAF positivity does 
not factor into treatment options for node negative disease 
and has no known prognostic significance, but it informs 
management in the metastatic setting [38, 39]. 
In this study, we also found a significant association 
between Reg4, CD44, and CD44ICD; demonstrating for 
the first time that this pathway is biologically relevant 
outside of cancer cell lines alone. While the exact 
mechanism of Reg4 has long remained a mystery, our lab 
(unpublished data) has noted that exogenous Reg4 acts 
through the extracellular CD44 receptor. This interaction 
Figure 5: Pen-CD44ICD peptides interfering with nuclear CD44ICD activity inhibit stemness of CRC cells. As assessed 
by spheroid formation assays using HCT116 and HT29 CRC cells, Reg4 treatment increased the number and size of spheroids whereas 
higher doses of SP (50 μg/ml) and DP (50 μg/ml) significantly decreased it; no change was observed with an equivalent dose of NP (50 
μg/ml). (A) Graphical representation of data is shown in lower panel A, where lower doses of NP, SP and DP (1 μg/ml and 10 μg/ml) 
exhibited no significant changes, hence served as experimental controls. Spheroid cultures of HCT116 and HT29 shown in (B) Reg4 further 
confirmed Reg4-mediated increase in the number and size of spheroids, whereas DP (50 μg/ml) significantly blocked Reg4-mediated 
effects. (*p < 0.05). 
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is hypothesized to trigger intramembranous proteolysis of 
CD44 and release of CD44ICD, or CD44 intracytoplasmic 
domain, to the nucleus activating a series of pro-metastatic 
and anti-apoptotic genes. Recent in vitro data from our 
lab reveals a direct interaction between Reg4 and the 
CD44, using a biotinylated Reg4 pull down assay and 
mass spectrometry. Our work has further demonstrated 
that Reg4 induces proteolytic cleavage of CD44, releasing 
CD44ICD into the nucleus. The direct interaction between 
these proteins works through intramembrane proteolysis 
(RIP)-based signaling, recently recognized as a common 
signaling mechanism used by a number of type 1 
transmembrane proteins including Notch, Delta and CD44 
[40]. Analogous to Notch signaling, y-secretase releases a 
74aa CD44 intracellular domain fragment (CD44ICD) into 
the nucleus [41, 42].
The first description of phorbol ester-induced 
proteolytic release of CD44ICD was reported in 
glioblastoma cells in 2001 [43]. Other neoplasms 
such as papillary thyroid carcinomas have been found 
to express CD44ICD to sustain cell proliferation via 
CREB-dependent transcriptional activation of Cyclin 
D1. Gonzalez et al. (2012) characterizes the CD44- 
CD44ICD pathway and its downstream genes, defining 
its critical role in various glycolytic pathways and cancer 
stem cell knockdown of CD44 by RNA interference or 
y-secretase inhibitors (GSIs) blocked proliferation, which 
was restored by CD44ICD overexpression. CD44ICD 
contains a nuclear localization signal and is a potent 
activator of oncogenic transcription [16, 44, 45]. Studies 
suggest that CD44ICD triggers a series of “stemness 
factors” in the nucleus such as nanog, sox-2, and oct-4 that 
lead to a pro-metastatic cancer phenotype with increased 
tumorigenicity [46]. Inhibition of CD44 proteolytic 
cleavage blocks the pro-proliferative properties of Reg4 in 
the lab, demonstrating that the CD44-CD44ICD pathway 
is the driving mechanism of Reg4 tumorigenicity. The 
significant association found in our study between Reg4, 
CD44, and CD44ICD gives biological credibility to this 
pathway within a clinical cohort of colon adenocarcinoma 
patients. This dose dependent relationship was seen both 
in percent field of protein expression and mean intensity 
of protein expression, suggesting the direct interaction of 
these proteins in a pathway rather than a mere association. 
Our study was limited by non-randomization and 
the size of the cohort with 94 total matched patients, 24 
of which had recurrent disease. Due to the retrospective 
nature, our data was incomplete and subject to sampling 
bias. Many of our patients had pathology analysis before 
BRAF and KRAS testing was standardized, and thus any 
association between survival, the Reg4 pathway and these 
proteins could not be assessed. The recurrence data from 
the TMA was reported by distant, not local metastasis and 
we did not have disease-specific mortality. However, our 
demographics including sex, recurrence rates, survivals, 
and microsatellite instability percentages did mirror that of 
the general population, leading us to believe that our TMA 
could serve as a representative sample. More prospective 
studies in an unselected population will be needed to 
confirm these findings. 
In conclusion, we have shown that in colon 
adenocarcinomas that express high levels of Reg4, this 
pathway becomes a major determinant of resistance and 
can affect survival in the metastatic setting. Our TMA 
analysis has also clinically validated the presence and 
significance of the Reg4-CD44-CD44ICD signaling 
pathway in tumor cells of human CRC patients. Our in 
vitro data shows that Reg4-CD44ICD signaling regulates 
proliferation and survival of the cancer stem cells, 
hence providing a unifying explanation for poor clinical 
outcomes with Reg4 and CD44/CD44ICD. We plan to 
validate these findings within a larger cohort of patients 
and continue to expand our work by interfering with this 
pathway to improve treatment in metastatic disease. 
MATERIALS AND METHODS
Patients for tissue microarray
A total of 93 stage II and III patients with colon 
adenocarcinoma who underwent surgical resection at 
Siteman Cancer Center between 2005 and 2012 were 
chosen to construct tissue microarray (TMA) slides of 
4 microns sections. Each TMA included 6 control tissue 
cores including: tonsil, appendix, kidney, nipple, brain, 
and placenta. Reg4 expression is upregulated in the 
appendix and thus served as the specificity control. 
The sources of these tissue cores were IRB-
approved closed human studies (IRB #201802060, Wash 
U St. Louis), informed consent previously obtained from 
patients to enter registry. The formalin-fixed and paraffin-
embedded (FFPE) tissue blocks were available for all 
cases. All the cases were re-reviewed by a pathologist and 
two separate 1mm tumor cores were obtained from distinct 
sections to account for tumor heterogeneity. These TMAs 
were constructed at the core facilities of Washington 
University School of Public Health under the auspices of 
Thomas Walsh. 
Study design
This was a retrospective translational cohort study 
using tissue specimens from patients that have undergone 
surgical resection at the Siteman Cancer center from 
2005–2012, with paired demographic information and 
clinical outcome data. Patients were selected from the 
Siteman Cancer registry database chronologically starting 
in 2005, where the first three patients to meet matching 
criteria were included after a recurrent case was identified. 
A sample size of 94 patients was derived assuming 50% 
positive CD44ICD samples, with a power ≥ 0.80 to detect 
a hazard ratio of 2.5, assuming a 3-year DFS 72% in 
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patients with colon cancer stage III. The power analysis 
was based on two-sample log-rank test at a significance 
level 0.05. 
Each recurrent case was paired with 1–4 non-
recurrent cases matched by TNM stage, age (+/– 5 years), 
sex, and chemotherapy administration (yes/no). Patients 
in the database are followed annually for life, with 
recurrence and vital status confirmed through the EMR 
by the Siteman Cancer registry if followed at Washington 
University or through letter/phone contact if at an outside 
clinical practice. The clinical endpoint examined was 
recurrent disease as defined by the primary oncologist 
based on imaging studies. 
The primary variable was CD44ICD, CD44, and 
Reg4 immunohistochemical staining determined by a 
pathologist, scored for intensity and percent staining. 
Additionally, an H-score or “histology” score was calculated 
for each protein, derived by multiplying percent staining of 
a protein by its intensity score. CD44ICD nuclear staining 
was chosen as it most closely reflected our cell-line model 
of CD44ICD activating “stemness” genes in the nucleus. 
The matched variables were age, sex, chemotherapy, and 
TNM stage. Specific chemotherapy regimen (e.g., FOLFOX 
or CapeOx) was not matched, but all patients received 
some form of 5-FU based chemotherapy. We also recorded 
multiple co-variables such as tumor size, MMR status, 
tumor laterality (left or right sided), tumor histology (poor, 
moderate, well), and years to recurrence. MMR status was 
reviewed to determine if there was any relationship between 
the Reg4 and microsatellite instability pathways. MSI-H 
status has also been associated with distinct recurrence 
rates by location and worse survival after recurrence, so this 
variable was identified to avoid a potential confounder [47]. 
The overall demographics of patients included in this TMA 
are shown in Table 1. 
The histology and tumor size were identified based 
on the official pathology report in the medical record. MMR 
status was identified through IHC staining of our TMA for 
MLH1/PMS2 and MSH2/MSH6 since most tumor sections 
were resected prior to standardized testing for microsatellite 
instability. Studies have corroborated that MMR status can 
be detected accurately by TMA in colon cancer [48, 49]. 
Antibodies
A rabbit monoclonal antibody specific to panCD44 
was purchased from Cell Signaling Technology (Danvers, 
MA, USA). Affinity-purified polyclonal antibodies from 
New Zealand rabbit specific to human Reg4 peptide 
(sequence: CRSWSGKSMGGNKH; immunogen: 
peptide-KLH conjugate) and from goat specific to human 
CD44ICD peptide (sequence: AVEDRKPSGLNGEAC; 
immunogen: Peptide-KLH conjugate) were custom 
synthesized and standardized at GeneScript 
(Piscataway, NJ, USA). These antibodies were used for 
immunohistochemical staining of TMAs. 
Penetratin-CD44ICD peptide
We chose the most conserved amino acid sequence 
of CD44ICD mature peptide (conserved through primitive 
species to human), and custom synthesized three variants 
of CD44ICD peptides with an attachment of short 16 amino 
acid sequence of Penetratin [RQIKIWFQNRRMKWKK] 
to facilitate their entry into the nucleus of C44-positive 
cells to interfere with the activity of host CD44ICD 
(Invitrogen, Carlsbad, CA, USA). The carboxyterminus 
residues were amidated and a proportion of each peptide 
was synthesized with a ‘Biotin’ group at the amino-
terminus. Peptides were either non-phosphorylated (NP) 
or were synthesized with single phosphoserine at position 
325 (SP), or with double phosphoserine at positions 323 
and 325 (DP) as shown in Figure 6. 
Immunohistochemistry
Endogenous peroxide in deparaffinized TMA slides 
were quenched in 1% Hydrogen Peroxide/Methanol and 
then subjected to antigen retrieval by steaming in Diva 
Decloaking Solution (Biocare Medical, Walnut Creek, 
CA, USA) in a pressure cooker at 15PSI for 3 minutes. 
Slides were then blocked with Avidin/Biotin blocking 
solution (Biocare) and incubated with primary antibodies 
overnight (CD44ICD 1:500, CD44 1:400, Reg IV 
1:500). The next day, slides were incubated in respective 
secondary antibodies (1:1000) followed by incubation 
in SA-HRP solution (1:1000; Jackson Immunoresearch). 
Slides were finally stained with Betazid DAB (Biocare), 
counterstained with hematoxylin, (7211, Richard Allan, 
Kalamazoo, MI, USA) and mounted to observe/score 
under phase-contrast microscope. 
Prior to our principal analysis, we confirmed the 
homogeneity of protein expression between the two cores 
(TMA A and TMA B) for each patient. A chi-squared 
analysis revealed no significant difference between 
percent protein expression or staining intensity between 
the two cores for either Reg4, CD44, or CD44ICD. The 
TMA was scored by a pathologist blinded to all clinical 
data, who characterized location of staining (membranous, 
cytoplasmic, nuclear), intensity of staining (weak, 
moderate, strong), and percent of field with positive 
staining. Additionally, nuclear CD44ICD was quantified 
using the Allred scoring system, an accepted scoring 
system used in nuclear hormonal quantification in breast 
cancer that includes intensity and percentage of nuclear 
staining.
Cell culture and reagents
Mycoplasma-tested human colorectal cancer (CRC) 
cell lines (HCT116, SW480 and HT29; American Type 
Culture Collection, Manassas, VA, USA) were grown 
in DMEM media containing 10% heat inactivated fetal 
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Figure 6: Generation of Penetratin-CD44ICD peptides. All peptides comprise 16 amino acid Penetrating sequence (underlined) 
followed by amino acid 318–340 from the CD44 intra-cytoplasmic domain (CD44ICD). Three different constructs of Pen-CD44ICD 
peptides were synthesized: non-phosphorylated (NP), with single phosphoserine at position 325 (SP) and with double phosphoserine at 
positions 323 and 325 (DP).
Table 1: TMA demographics
MMR Status
MMR intact 80 (86%)













Size Average 4.8 cm [2.35–7.25]











bovine serum (All from GIBCO by Life Technologies, 
Grand Island, NY, USA). Cell lines used for experiments 
were from passage number 3–30 at approximately 70–
80% confluency.
Cell proliferation assay
CRC cell proliferation was assessed by WST-1 
assay (Roche, Indianapolis, IN, USA). Briefly, the stable 
tetrazolium salt WST-1 is cleaved to a soluble formazan 
in viable cells. Therefore, the amount of formazan dye 
formed directly correlates to the number of metabolically 
active cells in the cultures. CRC cells (HT29 and 
SW480) grown in a 96-well culture plate were incubated 
with the WST-1 reagent for 4 hours. The formazan dye 
formed is then quantitated with a Synergy 2 multi-well 
spectrophotometer (BioTek, Winooski, VT). The measured 
absorbance directly correlates to the number of viable 
proliferative cells.
Spheroid forming assay
The spheroid forming culture is the most widely 
used in vitro functional assay for assessing growth of 
cancer stem cells [50]. CRC and PC cells were seeded 
in media containing EGF (1 ng/ml; R&D Systems, 
Minneapolis, MN, USA), insulin (0.4 μg/ml; Life 
Technologies, Grand Island, NY, USA) and Rock Inhibitor 
(10 µM; American Type Culture Collection, Manassas, 
VA) into the wells of low adhesion culture plate (Corning, 
NY, USA). Cells were grown 12 days in above-mentioned 
culture media and the number and size of growing 
spheroids were quantified microscopically.
Statistical analysis
Spearman’s correlation was used to study the 
association between individual proteins using percent 
mean expression (0–100%) and mean intensity (0, 1, 2, 
3) as scored blindly by the pathologist. Survival time 
was defined as time from initial surgical resection to 
death. Product-limit survival estimates were obtained 
to estimate survival probability and log-rank tests were 
used to compare survival probability between groups. 
Conditional logistic regression analysis was performed 
to examine association between disease recurrence and 
protein expression and intensity. All statistical tests were 
two-sided at significance level 0.05 and analysis was 
conducted using SAS9.4 (SAS Inc, Cary, NC, USA). 
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